Comparative study of inhibition at multiple stages of amyloid-beta self-assembly provides mechanistic insight.
The "amyloid cascade hypothesis," linking self-assembly of the amyloid-beta protein (Abeta) to the pathogenesis of Alzheimer's disease, has led to the emergence of inhibition of Abeta self-assembly as a prime therapeutic strategy for this currently unpreventable and devastating disease. The complexity of Abeta self-assembly, which involves multiple reaction intermediates related by nonlinear and interconnected nucleation and growth mechanisms, provides multiple points for inhibitor intervention. Although a number of small-molecule inhibitors of Abeta self-assembly have been identified, little insight has been garnered concerning the point at which these inhibitors intervene within the Abeta assembly process. In the current study, a julolidine derivative is identified as an inhibitor of Abeta self-assembly. To gain insight into the mechanistic action of this inhibitor, the inhibition of fibril formation from monomeric protein is assessed quantitatively and compared with the inhibition of two distinct mechanisms of growth for soluble Abeta aggregation intermediates. This compound is observed to significantly inhibit soluble aggregate growth by lateral association while having little effect on soluble aggregate elongation via monomer addition. In addition, inhibition of soluble Abeta aggregate association exhibits an IC(50) with a somewhat lower stoichiometric ratio than the IC(50) determined for inhibition of fibril formation from monomeric Abeta. This quantitative comparison of inhibition within multiple Abeta self-assembly assays suggests that this compound binds the lateral surface of on-pathway intermediates exhibiting a range of sizes to prevent their association with other aggregates, which is required for further assembly into mature fibrils.
Davis
Timothy J
TJ
Department of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
Soto-Ortega
Deborah D
DD
Kotarek
Joseph A
JA
Gonzalez-Velasquez
Francisco J
FJ
Sivakumar
Krishnamoothy
K
Wu
Laying
L
Wang
Qian
Q
Moss
Melissa A
MA
D000447:Aldehydes / Q000494:pharmacology; D000544:Alzheimer Disease / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism* / Q000648:ultrastructure; D052160:Benzothiazoles; D020128:Inhibitory Concentration 50; D008027:Light; D015394:Molecular Structure; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation; D011807:Quinolizines / Q000494:pharmacology; D012542:Scattering, Radiation; D012995:Solubility; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000494:pharmacology
C542803:8-hydroxy-2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinoline-9-carbaldehyde; D000447:Aldehydes; D016229:Amyloid beta-Peptides; D052160:Benzothiazoles; D010446:Peptide Fragments; D011807:Quinolizines; D013844:Thiazoles; C009462:thioflavin T